A truly interesting panel at Health Tech Forward on Automation in Clinical Trials with insilco t...

A truly interesting panel at Health Tech Forward on Automation in Clinical Trials with insilco trials and digitaltwins, with Orr Inbar, Vincent Lepreux, and Shola Oyewole.

QuantHealth' Orr Inbar shared an impressive case study with a biotech where their AI technology was able to reduce trial length by a year, reduce the number of patients required, and actually improve the clinical outcomes on the primary endpoint. He also sees a change in the narrative with the regulators on the topic of in-silico trials.

Vincent Lepreux mentioned what criteria VC investors are looking for in startups in the field, including the underlying AI data quality, the capability of actually being able to predict outcomes, and the ability of the company to get deals done with pharma and biotech companies. He is very optimistic on the potential of digital twins, having invested in several players in the area, and also sees increasing pharma appetite for these technologies.

Shola Adeyemi of United Therapeutics Corporation is developing digital twins of organs, often completely replacing animal models. He also shared that in-silico trials will enable more targeted trials for orphan diseases.